An Insight into the Interaction Between α-ketoamide- Based Inhibitor and Coronavirus Main Protease: A Detailed in Silico Study
Overview
Authors
Affiliations
The search for therapeutic drugs that can neutralize the effects of COVID-2019 (SARS-CoV-2) infection is the main focus of current research. The coronavirus main protease (M) is an attractive target for anti-coronavirus drug design. Further, α-ketoamide is proved to be very effective as a reversible covalent-inhibitor against cysteine proteases. Herein, we report on the non-covalent to the covalent adduct formation mechanism of α-ketoamide-based inhibitor with the enzyme active site amino acids by QM/SQM model (QM = quantum mechanical, SQM = semi-empirical QM). To uncover the mechanism, we focused on two approaches: a concerted and a stepwise fashion. The concerted pathway proceeds via deprotonation of the thiol of cysteine (here, Cys SγH) and simultaneous reversible nucleophilic attack of sulfur onto the α-ketoamide warhead. In this work, we propose three plausible concerted pathways. On the contrary, in a traditional two-stage pathway, the first step is proton transfer from Cys SγH to His Nδ forming an ion pair, and consecutively, in the second step, the thiolate ion attacks the α-keto group to form a thiohemiketal. In this reaction, we find that the stability of the tetrahedral intermediate oxyanion/hydroxyl group plays an important role. Moreover, as the α-keto group has two faces Si or Re for the nucleophilic attack, we considered both possibilities of attack leading to S- and R-thiohemiketal. We computed the structural, electronic, and energetic parameters of all stationary points including transition states via ONIOM and pure DFT method. Additionally, to characterize covalent, weak noncovalent interaction (NCI) and hydrogen-bonds, we applied NCI-reduced density gradient (NCI-RDG) methods along with Bader's Quantum Theory of Atoms-in-Molecules (QTAIM) and natural bonding orbital (NBO) analysis.
Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.
Atatreh N, Mahgoub R, Ghattas M J Enzyme Inhib Med Chem. 2025; 40(1):2460045.
PMID: 39912405 PMC: 11803818. DOI: 10.1080/14756366.2025.2460045.
Targeting SARS-CoV-2 Non-Structural Proteins.
Tam D, Lorenzo-Leal A, Hernandez L, Bach H Int J Mol Sci. 2023; 24(16).
PMID: 37629182 PMC: 10455537. DOI: 10.3390/ijms241613002.
La Monica G, Bono A, Lauria A, Martorana A J Med Chem. 2022; 65(19):12500-12534.
PMID: 36169610 PMC: 9528073. DOI: 10.1021/acs.jmedchem.2c01005.
Andi B, Kumaran D, Kreitler D, Soares A, Keereetaweep J, Jakoncic J Sci Rep. 2022; 12(1):12197.
PMID: 35842458 PMC: 9287821. DOI: 10.1038/s41598-022-15930-z.
Effect of pH on stability of dimer structure of the main protease of coronavirus-2.
Boonamnaj P, Pandey R, Sompornpisut P Biophys Chem. 2022; 287:106829.
PMID: 35635893 PMC: 9119281. DOI: 10.1016/j.bpc.2022.106829.